All posts

GTII stock has a huge upside, says Beacon

The market has not been kind to pot stocks over the past two years, and that includes Green Thumb Industries (Green Thumb Industries Stock Quote, Charts, News, Analysts, Financials CSE:GTII), whose share price is down over 70 per cent since May 2021.

But investors should be looking ahead instead of behind when it comes to GTII, according to Beacon Securities analyst Russell Stanley, who continued with a “Buy” rating on the stock and C$28 target price in a Monday report to clients. Stanley sees a potential catalyst in this week’s earnings report from Green Thumb and is calling for top and bottom line growth for the company over 2023 and 2024.

Ahead of Wednesday’s first quarter results from Green Thumb, due after market close, Stanley has forecasted revenue and adjusted EBITDA of $247 million and $76 million, respectively, with analysts’ consensus estimates at $250 million and $74 million, respectively. The analyst is also calling for cash from operations of $56 million for a 23 per cent margin. (All figures in US dollars except where noted otherwise.)

Stanley said he’ll be listening for management commentary on pricing pressures in the US cannabis market which have impacted margins. He noted that in the company’s fourth quarter 2022 earnings call in February, management said it was aiming to lessen the effect on profit of price compression by improving operating efficiencies and putting more efforts into establishing verticality, i.e., by selling its own house brands through GTII-owned stores.

Based in Chicago, Green Thumb currently generates revenue in 15 states in the US, with 18 manufacturing facilities and 79 operating dispensaries.

“We will also be listening for an update on New Jersey, which has been the primary driver of y/y growth for many MSOs. Finally, Florida will be of particularly interest, given last year’s announced partnership with Circle K,” Stanley wrote.

“With the adult-use legalization campaign having made significant progress on the signature gathering front, Florida’s potential importance continues to climb,” he said.

Further afield, the analyst thinks GTII’s revenue will move from $1,017 million in 2022 to $1,077 million in 2023 and to $1,272 million in 2024. On adjusted EBITDA the call is for $352 million in 2023 and $455 million in 2024.

Stanley said GTII is currently trading at 4.2x his 2024 EV/EBITDA forecast, which represents a 13 per cent discount to the 4.9x average among CSE-listed US cannabis operators.

“We continue to believe GTII deserves a premium valuation, given its strong EBITDA/cash flow margin track record and strong balance sheet,” he said.

At press time, Stanley’s C$28 target represented a one-year return of 192 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: gtii
Staff

Recent Posts

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

10 hours ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

16 hours ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

17 hours ago

Is Wolfspeed stock still a buy?

Ahead of the company's third quarter results, Roth MKM analyst Scott Irwin has maintained his "Buy" rating on Wolfspeed (Wolfspeed… [Read More]

18 hours ago

WELL Health inks five-year deal with Microsoft

It's become one of the biggest players in the Canadian healthcare space, now WELL Health (WELL Health Stock Quote, Chart,… [Read More]

2 days ago

Is Thomson Reuters stock a buy right now?

Its stock has made a since last October, but is there more upside left in Thomson Reuters (Thomson Reuters Stock… [Read More]

2 days ago